检索结果-南通市图书馆

实用口腔医学杂志 2008年第1期24卷 56-56页

作者： alan B．Carr Glen P．McGivney david T．Brown 张富强（主译）不详人民军医出版社出版

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

为岁月镀上金色的光华

现代装饰（家居） 2016年第5期 68-75页

作者： alan Wisniewski Alvaro Goula & Pablo Figuera Cristian Mohaded david Green & Eugenie De Loynes Daevas Design Gingerlily JSPR Kateryna Sokolova Lena Billmeier & david Baur Mme Mina Ben Miled Maud Opdebeck Peter Karpf Simla Sa Simon Legald 伏平范嘉苑 Eddingtons Ltd. Filipa Ricardo & Studio Porcel Michael Anastassiades studio

清晨的阳光爬满窗棂,清新而温暖,窗台上的花儿散发着淡淡的香气,沁人心脾。一个人的时光,你可以坐拥一杯茶的安暖,看蔚蓝的天空上白云悠悠,让一颗心在尘世浮躁中安静下来,感悟生活带给我们的点点滴滴的美好,在时光的百转干回中,品味岁... 详细信息

清晨的阳光爬满窗棂,清新而温暖,窗台上的花儿散发着淡淡的香气,沁人心脾。一个人的时光,你可以坐拥一杯茶的安暖,看蔚蓝的天空上白云悠悠,让一颗心在尘世浮躁中安静下来,感悟生活带给我们的点点滴滴的美好,在时光的百转干回中,品味岁月的静好。光阴茬苒,流年轻叹,每个人的心里都装着岁月的痕迹。当我们踩着岁月的台阶一步步地走向成熟,当我们睡眼惺忪地发现自己已不再年轻时。

关键词：生活带回中一杯茶难忘的记忆金属材质不自觉给你心灵深处简化结构念想

Silverline Audio Technology Sonatina音箱

维普期刊数据库

同方期刊数据库博看期刊评论

在线全文

学校读者我要写书评

暂无评论

高保真音响 2004年第2期 37-41页

作者： david

器材简介Silverline Audio Technology是alan Yun先生自香港移民到美国后于1996年成立的公司.

关键词： SilverlineAudioTechnology公司 Sonatina音箱四单元四分频设计三单元三分频设计

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

《可摘局部义齿修复学》

实用口腔医学杂志 2008年第2期24卷 251-251页

作者： alan B. Carr（） Glen P. McGivney（） david T. Brown（）张富强（主译）不详人民军医出版社出版

Building the new international science of the agriculture-food-water-environment Nexus in China and the world

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Ecosystem Health and Sustainability 2016年第11期2卷 2-8页

作者： Xinguang Zhu Martin Parry Yonglong Lu Matthew Heard Guangguo Ying Simon Vaughan Jianbo Shen alan Jenkins Yunpeng Wang Silvia Lacorte Tingping Ouyang Francisco Pedrero Salcedo Jun Niu John Quinton Chunling Luo Fusuo Zhang Gan Zhang William Davies Kevin Jones david Tyfield CAS Key laboratory for Computational Biology CAS-MPG Partner Institute for Computational BiologyChinese Academy of SciencesShanghaiChina Lancaster Environment Centre Lancaster UniversityLancasterUK Research Centre for Eco-Environmental Sciences Chinese Academy of SciencesBeijingChina Centre for Ecology and Hydrology WallingfordUK Guangzhou Institute of Geochemistry Chinese Academy of SciencesGuangzhouChina Rothamsted Research HarpendenUK China Agricultural University BeijingChina Centre for Ecology and Hydrology LancasterUK Consuejo Superior de Investigaciones Cientificas BarcelonaSpain International Research and Innovation Centre for the Environment(I-RICE) GuangzhouChina

The multiple,complex and systemic problems of the agriculture-food-water-environment nexus(“Nexus”)are among the most significant challenges of the 21st *** is a key site for Nexus research amidst profound socio-environmental *** policy implications of these problems have been authoritatively summarized *** study presents discussions at an international workshop in Guangzhou that asked instead“What science is needed to deliver the growing policy commitments regarding these challenges?And,What changes are needed to the science itself?”Understanding and effective intervention regarding the Nexus calls for a paradigm shift:to a new kind of science of(capacity for)international,interdisciplinary,and impactful research working with and within complex socio-natural *** here argue that science must become proactive in approach,striving only for“minimal harm”not“silver bullet”solutions,and adopting an explicitly long-term strategic ***,these arguments lead to calls for reorienting science and science policy in three ways:from short-term remediation to longer-term optimization;from a focus on environmental threats to one on the opportunities for international collaborative learning;and toward supporting new forms of scientific *** bring these points together by recommending a new form of scientific institution:a global network of collaborative Nexus Centres,under the umbrella of a global Food Nexus Organization akin to those of the human genome and proteome.

关键词： agriculture-food-water-environment Nexus China complex systems food security international col-laboration new science.

Integrative phosphoproteomics defines two biologically distinct groups of KMT2A rearranged acute myeloid leukaemia with different drug response phenotypes

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Signal Transduction and Targeted Therapy 2023年第3期8卷 1318-1331页

作者： Pedro Casado Ana Rio-Machin Juho JMiettinen Findlay Bewicke-Copley Kevin Rouault-Pierre Szilvia Krizsan Alun Parsons Vinothini Rajeeve Farideh Miraki-Moud david CTaussig Csaba Bödör John Gribben Caroline Heckman Jude Fitzgibbon Pedro R.Cutillas Cell Signalling and Proteomics Group Centre for Genomics and Computational BiologyBarts Cancer InstituteQueen Mary University of LondonLondon EC1M6BQUK Centre for Genomics and Computational Biology Barts Cancer InstituteQueen Mary University of LondonLondon EC1M6BQUK Institute for Molecular Medicine Finland-FIMM HiLIFE-Helsinki Institute of Life ScienceiCAN Digital Precision Cancer Medicine FlagshipUniversity of HelsinkiHelsinkiFinland Centre for Haemato-Oncology Barts Cancer InstituteQueen Mary University of LondonLondon EC1M6BQUK HCEMM-SU Molecular Oncohematology Research Group 1st Department of Pathology and Experimental Cancer ResearchSemmelweis University BudapestBudapestHungary Cancer Research UK Cancer Therapeutics Unit Division of Cancer TherapeuticsThe Institute of Cancer ResearchSuttonUK a The alan Turing Institute The British Library2QR96 Euston RdLondon NW12DBUK

Acute myeloid leukaemia(AML)patients harbouring certain chromosome abnormalities have particularly adverse *** these patients,targeted therapies have not yet made a significant clinical *** understand the molecular landscape of poor prognosis AML we profiled 74 patients from two different centres(in UK and Finland)at the proteomic,phosphoproteomic and drug response phenotypic *** data were complemented with transcriptomics analysis for 39 *** integration highlighted a phosphoproteomics signature that define two biologically distinct groups of KMT2A rearranged leukaemia,which we term MLLGA and *** presented increased DOT1L phosphorylation,HOXA gene expression,CDK1 activity and phosphorylation of proteins involved in RNA metabolism,replication and DNA damage when compared to MLLGB and no KMT2A rearranged *** was particularly sensitive to 15 compounds including genotoxic drugs and inhibitors of mitotic kinases and inosine-5-monosphosphate dehydrogenase(IMPDH)relative to other ***-risk KMT2A-MLLT3 cases were mainly represented in a third group closer to MLLGA than to *** expression of IMPDH2 and multiple nucleolar proteins was higher in MLLGA and correlated with the response to IMPDH inhibition in KMT2A rearranged leukaemia,suggesting a role of the nucleolar activity in sensitivity to *** summary,our multilayer molecular profiling of AML with poor prognosis and KMT2A-MLLT3 karyotypes identified a phosphoproteomics signature that defines two biologically and phenotypically distinct groups of KMT2A rearranged *** data provide a rationale for the potential development of specific therapies for AML patients characterised by the MLLGA phosphoproteomics signature identified in this study.

关键词： metabolism signature biologically

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

冲入战团

商业周刊（中文版） 2011年第2期 52-60页

作者：埃里克·波利（Eric Pooley）戴维·韦尔奇（david Wekh）艾轮·奥斯曼（alan Ohnsman）杨鸣娟（译）

在一个多雾的12月的早晨，加利福尼亚州Marin县101高速公路上的大部分驾驶员都没有注意到从他们身旁驶过的这辆车头短小的黑色汽车。不过，偶尔也会有人突然注意到它，他们要么翘起拇指以示赞许，要么迅速地拿出手机拍张照片，冈为他们... 详细信息

在一个多雾的12月的早晨，加利福尼亚州Marin县101高速公路上的大部分驾驶员都没有注意到从他们身旁驶过的这辆车头短小的黑色汽车。不过，偶尔也会有人突然注意到它，他们要么翘起拇指以示赞许，要么迅速地拿出手机拍张照片，冈为他们从未见过在旁边车道经过的这辆汽车：它就是日产公司的Ieaf——世界上第一辆规模化生产的消费级电动汽车。

关键词：加利福尼亚州电动汽车规模化生产高速公路日产公司驾驶员消费

钠-葡萄糖共转运蛋白-2抑制剂或胰高血糖素样肽-1受体激动剂治疗成人2型糖尿病:临床实践指南

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

英国医学杂志中文版 2021年第9期24卷 523-531页

作者： Sheyu Li Per Olav Vandvik Lyubov Lytvyn Gordon H Guyatt Suetonia C Palmer Rene Rodriguez-Gutierrez Farid Foroutan Thomas Agoritsas Reed A C Siemieniuk Michael Walsh Lawrie Frere david J Tunnicliffe Evi V Nagler Veena Manja Bjφrn Olav Asvold Vivekanand Jha Mieke Vermandere Karim Gariani Qian Zhao Yan Ren Emma Jane Cartwright Patrick Gee alan Wickes Linda Fems Robin Wright Ling Li Qiukui Hao Reem A Mustafa 无郭鹤鸣(译) Chengdu China Chinese Evidencebased Medicine Center Cochrane China Center and MAGIC China CenterWest China HospitalSichuan UniversityChengduChina University of Oslo OsloNorway MAGIC Evidence Ecosystem Foundation Department of Health Research Methods Evidence and ImpactMcMaster UniversityHamiltonONCanada Department of Medicine McMaster UniversityHamiltonONCanada Department of Medicine University of OtagoChristchurchNew Zealand Plataforma INVEST Medicina UANL-KER Unit(KER Unit Mexico) Subdireccion de InvestigacionUniversidad Autonoma de Nuevo LeonMonterrey64460Mexico Knowledge and Evaluation Research Endocrinology Mayo ClinicRochesterMN55905USA Endocrinology Division Department of Internal MedicineUniversity Hospital"Dr.Jose E.Gonzalez"Universidad Autonoma de Nuevo LeonMonterrey64460Mexico Ted Rogers Center for Heart Research Canada Service of Endocrinology DiabetesNutrition and Patient Therapeutic EducationGeneva University HospitalsGenevaSwitzerland Newbridge Surgery BathUK Sydney School of Public Health The University of SydneySydneyAustralia Centre for Kidney Research The Children's Hospital at WestmeadSydneyAustralia Renal Division Ghent University HospitalBelgium University of California Davis USA Department of Endocrinology Clinic of MedicineSt Olavs HospitalTrondheim University HospitalTrondheimNorway K.G.Jebsen Center for Genetic Epidemiology Department of Public Health and NursingNTNUNorwegian University of Science and TechnologyTrondheimNorway The George Institute for Global Health UNSWIndia School of Public Health Imperial CollegeLondonUK Prasanna School of Public Health Manipal Academy of Higher EducationManipalIndia Department of Public Health and Primary Care KU LeuvenLeuvenBelgium International Medical Center/Ward of General Practice West China HospitalSichuan UniversityChengduChina London UK Founder&CEHD iAdvorateInc.VirginiaPatient partner Patient partner The Center of Gerontology and Geriatrics/National Clinical Research Center for Geriatr

临床问题对于存在不同心血管风险及肾脏结局的2型糖尿病患者,在原有生活方式干预和/或其他降糖药物的基础上加用钠-葡萄糖共转运蛋白2(SGLT-2)抑制剂和胰高血糖素样肽1(GLP-1)受体激动剂的获益及风险是什么?现行做法几十年来,2型糖尿病... 详细信息

临床问题对于存在不同心血管风险及肾脏结局的2型糖尿病患者,在原有生活方式干预和/或其他降糖药物的基础上加用钠-葡萄糖共转运蛋白2(SGLT-2)抑制剂和胰高血糖素样肽1(GLP-1)受体激动剂的获益及风险是什么?现行做法几十年来,2型糖尿病的治疗决策都以控制血糖为主导。SGLT-2抑制剂和GLP-1受体激动剂在传统观念中常被用于二甲双胍治疗后血糖仍控制不佳的患者。目前这一现状已经发生了改变,这得益于多项临床研究结果。研究显示SGLT-2抑制剂和GLP-1受体激动剂拥有独立于药物降糖作用之外的对于动脉粥样硬化性心血管病(CVD)和慢性肾脏病(CKD)的获益。建议本指南阐述了针对不同风险分层的成人2型糖尿病患者使用SGLT-2抑制剂或GLP-1受体激动剂的建议。•伴有3种或更少的心血管风险因素且不存在CVD或CKD:不建议启动SGLT-2抑制剂或GLP-1受体激动剂治疗。(推荐等级:弱)•伴有3种以上心血管风险因素且不存在CVD或CKD:建议启动SGLT-2抑制剂治疗,不建议启动GLP-1受体激动剂治疗。(推荐等级:弱)•已经存在CVD或CKD:建议启动SGLT-2抑制剂治疗和GLP-1受体激动剂治疗。(推荐等级:弱)•已经存在CVD和CKD:建议启动SGLT-2抑制剂治疗(推荐等级:强)和GLP-1受体激动剂治疗。(推荐等级:弱)•对于那些想要进一步降低CVD和CKD结局风险的患者:推荐优先启用SGLT-2抑制剂治疗而非GLP-1受体激动剂治疗。(推荐等级:弱)这项指南是如何制订的一个由患者、临床医生和方法学家共同组成的国际小组提出了这些推荐意见。这些推荐意见基于可信度较高的指南的标准,并使用GRADE分级方法进行评估。该小组采用了息者个体化的观点。证据一项关于获益与风险的系统综述和网络meta分析(764项随机对照研究,包括421346例参与者)发现SGLT-2抑制剂和GLP-1受体激动剂可以降低总体死亡率、心肌梗死发生率、终末期肾病或肾衰竭的发生率(中等至高等质量的证据)。在不同的亚组中这些药物对卒中、因心力衰竭所致住院和其他主要不良事件有不同的影响。药物绝对获益的程度因患者个体风险的不同有很大的差异。(例如,对于接受了超过5年药物治疗的1000例患者,在最低风险人群中死亡人数减少了5人,在最高风险人群中死亡人数减少了48人)。一项关于预后的综述确认了14种风险预测模型,其中一种(RECODe)在证据总结中报告了大部分基线风险评估数据,小组利用该模型以支持风险分层的建议。考虑到患者的价值观及个体差异,指南推荐的支撑证据包括一项对已发表论文的系统综述、一项患者焦点小组研究、一项临床问题总结,以及一项指南调查。指南解读我们依据不同的CVD和CKD风险水平,综合考虑获益、风险和其他因素的平衡,以及每一个风险组别的实际问题,来对推荐意见进行分层。本指南强烈建议CVD和CKD患者使用SGLT-2抑制剂治疗,这说明专家组认为其具有显著的获益。而对于其他成人2型糖尿病患者,推荐等级较弱,这说明专家组想要在获益、风险及治疗花费上取得一个更好的平衡。临床医生通过该指南可以使用可靠的风险计算模型,如RECODe,来明确其患者的个体心血管和肾脏疾病风险。医患交互式总结临床证据和制订决策有助于患者知晓治疗选择,包括进行共同决策。2型糖尿病人群(全球患病率不断增长1-2)正面临着不断增加的心血管疾病、肾脏病和其他并发症的风险3。数十年来,2型糖尿病的管理始终以控制血糖及糖化血红蛋白(HbA1c)为治疗目标4-5,但是,最近的高质量随机对照研究已经对这种以血糖为中心的治疗模式发起了挑战。研究结果显示,强化血糖控制未必会降低大血管不良事件,它还可能带来不利影响监管机构现在要求新型糖尿病药物必须证明其具有心血管和肾脏获益才能获得批准。对两类新药--钠-葡萄糖共转运蛋白2(SGLT-2)抑制剂和胰高血糖素样肽1(GLP-1)受体激动剂(见框图1)的临床试验结果显示,在现有治疗方案(常规治疗)之上加用这些药物,对死亡、心肌梗死、卒中、心力衰竭和肾脏的结局(如进展为终末期肾病)都有获益8-12。

关键词：胰高血糖素样肽1 终末期肾病临床研究结果心血管风险 meta分析临床试验结果临床证据控制血糖

The Physiological Effects of a Walking to Music Intervention in Adults with Intermediate Hyperglycemia

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Identification of new genetic risk factors for prostate cancer

Open Journal of Endocrine and Metabolic Diseases（内分泌与新陈代谢疾病期刊） 2021年第1期

作者： Maria Faulkner Marie Murphy Gareth Davison david Rowe Allan Hewitt alan Nevill Ellie Duly Tom Trinick Andrea M. McNeilly

来源：评论

学校读者我要写书评

暂无评论

Asian Journal of Andrology 2009年第1期11卷 49-55页

作者： Michelle Guy Zsofia Kote-Jarai Graham G. Giles Ali Amin Al Olama Sarah K. Jugurnauth Shani Mulholland Daniel A. Leongamomlert Stephen M. Edwards Jonathan Morrison Helen I. Field Melissa C. Southey Gianluca Severi Jenny L. Donovan Freddie C. Hamdy david R Dearnaley Kenneth R. Muir Charmaine Smith Melisa Bagnato Audrey T. Ardern-Jones Amanda L. Hall Lynne T. O＇Brien Beatrice N. Gehr-Swain Rosemary A. Wilkinson Angela Cox Sarah Lewis Paul M. Brown Sameer G. Jhavar Malgorzata Tymrakiewicz Artitaya Lophatananon Sarah L. Bryant The UK Genetic Prostate Cancer Study Collaborators British Association of Urological Surgeons＇ Section of Oncology and The UK ProtecT Study Collaborators alan Horwich Robert A. Huddart Vincent S. Khoo Christopher C. Parker Christopher J. Woodhouse alan Thompson Tim Christmas Chris Ogden Cyril Fisher Charles Jameson Colin S. Cooper Dallas R. English John L. Hopper david E. Neal Douglas E Easton Rosalind A. Eeles Section of Cancer Genetics The Institute of Cancer Research Sutton Surrey SM2 5NG UK Cancer Epidemiology Centre The Cancer Council Victoria Carlton VIC 3053 Australia Centre for Molecular Environmental Genetic and Analytic Epidemiology The University of Melbourne Carlton VIC 3053 Australia Cancer Research UK Genetic Epidemiology Unit University of Cambridge Strangeways Laboratory Worts Causeway Cambridge CB1 8RN UK Department of Oncology University of Cambridge Strangeways Laboratory Worts Causeway Cambridge CB1 8RN UK Genetic Epidemiology Laboratory Department of Pathology The University of Melbourne Parkville VIC 3052 Australia Department of Social Medicine University of Bristol Bristol BS8 2PR UK Academic Urology Unit University of Sheffield Sheffield SIO 2JF UK The Royal Marsden NHS Foundation Trust Sutton Surrey SM2 5PT and London SW3 6JJ UK University of Nottingham Medical School Queens Medical Centre Nottingham NG7 2UH UK Institute for Cancer Studies University of Sheffield Sheffield SIO 2RX UK Surgical Oncology （Uro-Oncology S4） Departments of Oncology and Surgery University of Cambridge Addenbrooke＇s Hospital Cambridge CB2 2QQ UK A full list of authors is provided in the Supplementary Note online Ka Shing Centre Cambridge CB2 ORE UK Cancer Research UK Cambridge Research Institute Li Ka Shing Centre Cambridge CB2 ORE UK.

There is evidence that a substantial part of genetic predisposition to prostate cancer （PCa） may be due to lower penetrance genes which are found by genome-wide association studies. We have recently conducted such a study and seven new regions of the genome linked to PCa risk have been identified. Three of these loci contain candidate susceptibility genes： MSMB, LMTK2 and KLK2/3. The MSMB and KLK2/3 genes may be useful for PCa screening, and the LMTK2 gene might provide a potential therapeutic target. Together with results from other groups, there are now 23 germline genetic variants which have been reported. These results have the potential to be developed into a genetic test. However, we consider that marketing of tests to the public is premature, as PCa risk can not be evaluated fully at this stage and the appropriate screening protocols need to be developed. Follow-up validation studies, as well as studies to explore the psychological implications of genetic profile testing, will be vital prior to roll out into healthcare.

关键词： prostate cancer genetics susceptibility loci SNPs relative risks